{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:11:25Z","timestamp":1768529485075,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.clcc.2020.02.014","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T12:15:00Z","timestamp":1583496900000},"page":"e110-e116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-na\u00efve Metastatic Colorectal Cancer Patients Prospectively Collected"],"prefix":"10.1016","volume":"19","author":[{"given":"Javier","family":"Sastre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia de la","family":"Orden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Bando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milagros","family":"Balb\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5335-2726","authenticated-orcid":false,"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarai","family":"Palanca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Isabel","family":"Peligros Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Mediero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-2105","authenticated-orcid":false,"given":"Patricia","family":"Llovet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia Moreno","family":"Moral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Maria","family":"Vi\u00e9itez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Garc\u00eda-Alfonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia Gil","family":"Calle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jos\u00e9","family":"Ortiz-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7399-7484","authenticated-orcid":false,"given":"Antonieta","family":"Salud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Quintero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"D\u00edaz-Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2020.02.014_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jnci\/djq456","article-title":"Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis","volume":"103","author":"Masi","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clcc.2020.02.014_bib2","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2020.02.014_bib3","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.02.014_bib4","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 Trials","volume":"3","author":"Tejpar","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2020.02.014_bib5","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.clcc.2020.02.014_bib6","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","article-title":"Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.02.014_bib7","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/annonc\/mdp463","article-title":"Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents","volume":"21","author":"Tol","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.02.014_bib8","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1634\/theoncologist.2012-0048","article-title":"Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study","volume":"17","author":"Sastre","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2020.02.014_bib9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2020.02.014_bib10","doi-asserted-by":"crossref","first-page":"e7287","DOI":"10.1371\/journal.pone.0007287","article-title":"Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer","volume":"4","author":"Sartore-Bianchi","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2020.02.014_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","volume":"100","author":"Koopman","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2020.02.014_bib12","first-page":"280","article-title":"Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab","volume":"12","author":"Sastre","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2020.02.014_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/jmedgenet-2011-100714","article-title":"Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification","volume":"49","author":"Parsons","year":"2012","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.clcc.2020.02.014_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00432-016-2275-4","article-title":"Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer","volume":"143","author":"Nakaji","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clcc.2020.02.014_bib15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/annonc\/mdm583","article-title":"Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables","volume":"19","author":"Sastre","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.02.014_bib16","first-page":"115","article-title":"Circulating tumor cell enumeration in a phase II trial of a four-drug regimen in advanced colorectal cancer","volume":"14","author":"Krebs","year":"2015","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2020.02.014_bib17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/15384047.2015.1030555","article-title":"Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation","volume":"16","author":"Das","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clcc.2020.02.014_bib18","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/15384047.2015.1026508","article-title":"Circulating tumor cell levels are elevated in colorectal cancer patients with high tumor burden in the liver","volume":"16","author":"Kaifi","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clcc.2020.02.014_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.4251\/wjgo.v8.i1.128","article-title":"Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases","volume":"8","author":"Cho","year":"2016","journal-title":"World J Gastrointest Oncol"},{"key":"10.1016\/j.clcc.2020.02.014_bib20","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s13277-013-0763-6","article-title":"Are high initial CEA and CA 19-9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer?","volume":"34","author":"Selcukbiricik","year":"2013","journal-title":"Tumour Biol"},{"key":"10.1016\/j.clcc.2020.02.014_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/1471-2407-12-347","article-title":"Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer","volume":"12","author":"Kim","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clcc.2020.02.014_bib22","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/annonc\/mdu252","article-title":"Clinicopathologic characteristics and gene expression analyses of non-KRAS 12\/13, RAS-mutated metastatic colorectal cancer","volume":"25","author":"Morris","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.02.014_bib23","doi-asserted-by":"crossref","first-page":"e91739","DOI":"10.1371\/journal.pone.0091739","article-title":"Microsatellite stable colorectal cancers stratified by the BRAF V600E mutation show distinct patterns of chromosomal instability","volume":"9","author":"Bond","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2020.02.014_bib24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1080\/15384047.2016.1195048","article-title":"BRAF V600E mutation in metastatic colorectal cancer: methods of detection and correlation with clinical and pathologic features","volume":"17","author":"Roma","year":"2016","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clcc.2020.02.014_bib25","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/annonc\/mdw261","article-title":"Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group","volume":"27","author":"Modest","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.02.014_bib26","doi-asserted-by":"crossref","first-page":"e84604","DOI":"10.1371\/journal.pone.0084604","article-title":"BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients\u2019 outcome","volume":"8","author":"Saridaki","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clcc.2020.02.014_bib27","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/ijc.25555","article-title":"Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation","volume":"128","author":"Tie","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clcc.2020.02.014_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/bjc.2015.399","article-title":"Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer","volume":"114","author":"Loupakis","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2020.02.014_bib29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1002\/jso.23895","article-title":"Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers","volume":"111","author":"Lan","year":"2015","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.clcc.2020.02.014_bib30","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-11-2410","article-title":"Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review","volume":"18","author":"Liao","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2020.02.014_bib31","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820300372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820300372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:06:40Z","timestamp":1761520000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002820300372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1533002820300372"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2020.02.014","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-na\u00efve Metastatic Colorectal Cancer Patients Prospectively Collected","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2020.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}